 The stock price of TG Therapeutics NASDAQ: TGTX, a commercial stage biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases, has seen a large 57 fall over the last month, while it is down 41 over the last five trading days. 